Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02692209 · ClinicalTrials.gov registry record

A Multi-Reader Multi-Case Pivotal Trial

A clinical trial of Breast Cancer, sponsored by Fujifilm Medical Systems USA.

Completed
Registry status
298
Enrollment target
5
Study locations

NCT02692209: Completed study of Breast Cancer, sponsored by Fujifilm Medical Systems USA.

NCT02692209 is a study of Breast Cancer that has completed, run by Fujifilm Medical Systems USA. The registered enrollment target is 298 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (89% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02692209, a study of Breast Cancer, has completed, sponsored by Fujifilm Medical Systems USA.

COMPLETED
Registry status
298 participants
Enrollment target
5
Study locations

Study Summary

The purpose of this pivotal reader study is to assess the comparative accuracy of Fujifilm FFDM plus DBT versus FFDM alone in the detection of breast cancer.

Conditions Studied

Interventions

  • DEVICE FFDM Plus DBT
  • DEVICE FFDM Alone

Study Locations (5)

Arizona

  • Scottsdale Medical Imaging, Ltd - Scottsdale

Iowa

  • University of Iowa Hospitals and Clinics - Iowa City

New York

  • Elizabeth Wende Breast Care, LLC (EWBC) - Rochester

North Carolina

  • University of North Carolina - at Chapel Hill - Chapel Hill

Texas

  • University of Texas Health Science Center at San Antonio - San Antonio

Trial Details

FieldValue
Enrollment Target 298 participants
Start Date 2015-12
Est. Completion 2016-01

Sponsor

Fujifilm Medical Systems USA

13 total trials

What the Registry Record Tells You About NCT02692209

The ClinicalTrials.gov registry entry for NCT02692209 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 298 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (89% lower). The listed sponsor is Fujifilm Medical Systems USA, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which FFDM Plus DBT is the first listed.

NCT02692209 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Arizona, Iowa, New York.

Frequently Asked Questions

What is clinical trial NCT02692209 about?

NCT02692209 is a clinical study titled "A Multi-Reader Multi-Case Pivotal Trial". The purpose of this pivotal reader study is to assess the comparative accuracy of Fujifilm FFDM plus DBT versus FFDM alone in the detection of breast cancer.

What is the current status of trial NCT02692209?

This trial is currently completed. The enrollment target is 298 participants. The study started on 2015-12. Estimated completion is 2016-01.

What conditions does trial NCT02692209 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT02692209?

The interventions under investigation include: FFDM Plus DBT (DEVICE), FFDM Alone (DEVICE).

Who is sponsoring clinical trial NCT02692209?

This trial is sponsored by Fujifilm Medical Systems USA, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02692209 being conducted?

This trial has 5 study locations across Arizona, Iowa, New York, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.